Fu, Y.; Rathod, D.; Abo-Ali, E.M.; Dukhande, V.V.; Patel, K.
EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma. Pharmaceutics 2019, 11, 504.
https://doi.org/10.3390/pharmaceutics11100504
AMA Style
Fu Y, Rathod D, Abo-Ali EM, Dukhande VV, Patel K.
EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma. Pharmaceutics. 2019; 11(10):504.
https://doi.org/10.3390/pharmaceutics11100504
Chicago/Turabian Style
Fu, Yige, Drishti Rathod, Ehab M. Abo-Ali, Vikas V. Dukhande, and Ketan Patel.
2019. "EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma" Pharmaceutics 11, no. 10: 504.
https://doi.org/10.3390/pharmaceutics11100504
APA Style
Fu, Y., Rathod, D., Abo-Ali, E. M., Dukhande, V. V., & Patel, K.
(2019). EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma. Pharmaceutics, 11(10), 504.
https://doi.org/10.3390/pharmaceutics11100504